Earnings Insights · SRPT · Q3 FY2026
Sarepta Therapeutics Q3 2026 Earnings: PMO Strength Offsets a Stabilized but Smaller ELEVIDYS Business
By AlgovestIQ ResearchPublished
Read Sarepta Therapeutics’s results announcement (Form 8-K, filed Nov 5, 2026)
Key earnings findings
Sarepta Therapeutics (SRPT) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Sarepta Therapeutics reported Q3 FY2026 revenue of $381.4M against the $352.2M analyst estimate, a 8.3% beat, and EPS of $0.13 against the $0.08 analyst estimate.
- Sarepta raised the lower end of its full-year 2026 total net product revenue guidance by $50M.
- SRPT closed at $17.82 on Nov 6, 2026, up 1.4% from $17.57 on Nov 5, 2026, the last close before the results were released.
Sources: Sarepta Therapeutics results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Sarepta Therapeutics beat earnings expectations?
- Revenue surprise across the last 8 reported quarters has ranged from 4.3% to 54.1%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Sarepta Therapeutics reported third-quarter revenue of $381.4M, down 5% year over year, and a GAAP loss of $0.27 per share, compared with a $0.50 loss a year earlier. Non-GAAP EPS turned positive at $0.13, while non-GAAP operating income reached $22.9M. The quarter showed that Sarepta’s exon-skipping PMO franchise remains resilient, but the investment case still depends heavily on whether ELEVIDYS can stabilize and eventually resume growth following its narrower ambulatory-only label.
Management raised the low end of its full-year product-revenue outlook by $50M and reduced the high end of its expense range by $25M. The more consequential near-term catalysts, however, are multiple-ascending-dose data for the DM1 and FSHD programs expected by year-end and regulatory discussions on a possible path to reintroduce ELEVIDYS for non-ambulatory patients.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $381.4M | Down 5% year over year |
| Net product revenue | $323.8M | Down 13% year over year |
| PMO net product revenue | $240.3M | Not provided |
| ELEVIDYS net product revenue | $83.5M | Not provided |
| Collaboration and other revenue | $57.6M | Up from $29.3M |
| GAAP operating loss | ($9.0M) | Improved from ($103.4M) |
| Non-GAAP operating income | $22.9M | Improved from ($35.7M) |
| GAAP net loss | ($28.5M) | Improved from ($50.6M) |
| Non-GAAP net income | $15.6M | Improved from ($12.9M) loss |
| GAAP diluted EPS | ($0.27) | Improved from ($0.50) loss |
| Non-GAAP diluted EPS | $0.13 | Improved from ($0.13) loss |
| Cash, cash equivalents, restricted cash and investments | $998.7M | Up from $953.8M at year-end 2025 |
The Bigger Story
Sarepta’s quarterly results were less about headline revenue growth than about the durability of the PMO franchise and the apparent stabilization of ELEVIDYS demand after a difficult period for the gene therapy.
ELEVIDYS revenue of $83.5M remained constrained by the product’s updated label, which limits use to ambulatory Duchenne muscular dystrophy patients. Total product revenue declined 13% year over year as lower ELEVIDYS sales more than offset continued growth in exon-skipping therapies.
Management characterized third-quarter ELEVIDYS enrollment-form activity as consistent with the second quarter and above the level seen at the start of 2026. That does not yet establish renewed growth, particularly because the treatment journey from enrollment form to infusion can take roughly six months. But it gives Sarepta a baseline against which to assess whether expanded commercial activity and new clinical evidence can improve demand.
The company is also positioning DM1 and FSHD as its next potential value drivers. Multiple-ascending-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD are expected in the fourth quarter. Sarepta has started preparing manufacturing supply for potential Phase 3 studies, though advancement will depend on the data and subsequent discussions with regulators.
Revenue and Operating Performance
Net product revenue totaled $323.8M, consisting of $240.3M from Sarepta’s PMO therapies and $83.5M from ELEVIDYS. The PMO franchise was the central commercial positive in the quarter, with management citing increased new-patient enrollments and ongoing adherence among existing patients.
ELEVIDYS remained the principal source of year-over-year pressure. Total revenue fell $18.0M to $381.4M, primarily because of lower ELEVIDYS volume after the label was restricted to ambulatory patients. The decline was partly offset by a $31.4M increase in contract-manufacturing revenue associated with commercial ELEVIDYS supply delivered to Roche.
That distinction matters for revenue quality. Contract manufacturing revenue lifted total sales, but it does not represent direct patient demand for ELEVIDYS in the U.S. Sarepta’s product revenue declined from $370.0M a year earlier to $323.8M in the third quarter.
For the first nine months of 2026, product revenue fell 34% to $983.0M. Total revenue declined a more modest 14% to $1.51B because collaboration and other revenue rose to $530.4M. That year-to-date figure included revenue associated with Roche’s declined option for certain program rights, a milestone from the first commercial ELEVIDYS dosing in Japan, and higher contract-manufacturing sales to Roche. Those items supported reported revenue but are not equivalent to recurring U.S. product demand.
Management expects ELEVIDYS revenue in the fourth quarter to trend in line with the $83.5M reported in the third quarter, subject to the normal variability of a one-time gene therapy. The company has not provided a specific 2027 ELEVIDYS forecast and said it wants to see longer-term demand trends before offering more detailed timing for a return to growth.
Profitability and Margins
Sarepta narrowed its GAAP operating loss to $9.0M from $103.4M a year ago and produced non-GAAP operating income of $22.9M, compared with a $35.7M non-GAAP operating loss in the prior-year quarter.
The improvement was driven largely by lower R&D expense. GAAP R&D declined $136.4M to $82.5M, primarily because the prior-year quarter included a $100M milestone payment to Arrowhead Pharmaceuticals. Sarepta also benefited from lower clinical and manufacturing spending following its 2025 pipeline reprioritization and restructuring.
That comparison should be viewed carefully. The sharp year-over-year profit improvement reflects both cost discipline and the absence of a large prior-year milestone expense, rather than a straightforward improvement in commercial scale.
SG&A moved in the opposite direction. GAAP SG&A rose $26.7M to $118.6M, while non-GAAP SG&A increased $20.5M to $97.6M. The year-earlier period benefited from reversals of stock-compensation and incentive-compensation accruals related to the restructuring, making the comparison unfavorable.
Gross-margin pressure was also notable. Cost of sales increased 25% to $188.5M, including take-or-pay charges related to non-cancelable manufacturing commitments for inventory Sarepta elected not to produce. Management said product-revenue gross margin was 59% in the quarter, with take-or-pay charges reducing that measure by roughly 19 percentage points.
The company disclosed a $62.0M take-or-pay charge in the quarter and year to date related to Catalent manufacturing obligations. Cost of sales also increased because of product shipments to Roche and write-offs of certain batches that did not meet quality specifications under the Roche collaboration agreement. These manufacturing costs show that the reduced ELEVIDYS demand environment can create operating friction beyond lost revenue.
Below operating income, other expense was $16.7M, compared with $35.0M of other income a year ago. The change reflected the loss of gains from strategic investments following the August 2025 sale of Sarepta’s Arrowhead investment, partly offset by higher interest expense on the company’s 2030 notes.
Demand, Customers and Pricing
Management said physician willingness to treat with ELEVIDYS remains solid and that some prescribers who had paused activity are returning to treatment decisions. It attributed the stabilization in part to longer-term data from the EMBARK study and new data in patients ages 8 to 12, an age range in which functional decline can accelerate.
Sarepta presented two-year results showing durable functional benefit in ambulatory patients treated at ages 8 to 12 versus a matched external control group. It also presented early data from the Phase 4 ENDURE study evaluating liver-risk mitigation approaches. In the subset receiving prophylactic sirolimus, no acute liver injury events were observed, although management described the findings as preliminary.
The central demand issue remains benefit-risk confidence in ELEVIDYS after liver-safety concerns and the subsequent label restriction. Management is trying to rebuild adoption through physician education, a larger field organization, and long-term efficacy evidence. Whether that effort translates into higher enrollment forms and infusions is still unproven.
The PMO franchise is also facing a future competitive consideration. Management expects a potential competing exon 51-skipping therapy could receive approval in January 2027. Sarepta believes broad switching among stable patients would be unlikely immediately, citing its established reimbursement pathways and long-term real-world evidence, but it acknowledged that any market impact could become more visible later in 2027.
What is Sarepta’s guidance for full-year 2026?
Sarepta raised the lower end of its full-year 2026 total net product revenue guidance by $50M. The company now expects:
- Total net product revenue of $1.25B to $1.3B
- Combined non-GAAP R&D and SG&A expense of $800M to $825M
The revised expense range lowers the prior high end by $25M.
For the fourth quarter, management expects ELEVIDYS net product revenue to trend in line with the $83.5M reported in the third quarter, while the PMO franchise is expected to remain strong. Sarepta did not issue formal EPS, operating-income, or cash-flow guidance.
On the pipeline, management expects multiple-ascending-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD by year-end. Sarepta is preparing for possible registrational development, including clinical manufacturing, but has not committed to a final pivotal-study design, dose, or regulatory path.
The company expects to complete enrollment in ENDEAVOR Cohort 8 by year-end and plans to engage the FDA in the first quarter of 2027 after obtaining 12-week safety data. That study evaluates whether prophylactic sirolimus can reduce acute liver injury in non-ambulatory ELEVIDYS patients. Sarepta said it will not resume enrollment in the ENVISION study, which had been on hold for more than a year.
Balance Sheet, Cash Flow and Capital
Sarepta ended the quarter with $998.7M in cash, cash equivalents, restricted cash, and investments, up from $953.8M at the end of 2025. Management said the base business generated nearly $300M of cash year to date after adjusting for $250M in collaboration payments made to Arrowhead.
The company’s liquidity provides capacity to fund near-term pipeline work, but debt remains an important consideration. Sarepta reported $158.0M of current debt and $699.4M of long-term debt at quarter-end. Management said preserving financial flexibility ahead of the maturity of its 2027 notes is a medium-term capital-allocation priority.
Shares outstanding increased to 107.9 million at September 30 from 105.0 million at the end of 2025. Investors should monitor future financing decisions, particularly if Sarepta advances both DM1 and FSHD into late-stage trials while managing upcoming debt maturities.
What Investors Should Watch
1. ELEVIDYS demand stabilization
Quarterly ELEVIDYS revenue and enrollment-form activity will determine whether the third quarter marked a true demand floor or merely a temporary plateau. Management expects fourth-quarter revenue to remain roughly in line with the third quarter, making further stabilization the near-term test.
2. DM1 and FSHD multiple-ascending-dose data
The year-end readouts are the company’s most important pipeline events. Investors should focus on target knockdown, downstream biological effects, dose response, and tolerability rather than placing too much weight on early functional outcomes from small cohorts.
3. Path back to non-ambulatory ELEVIDYS use
ENDEAVOR Cohort 8 is now Sarepta’s primary route toward discussions with the FDA about the non-ambulatory population. The key evidence will be whether the sirolimus-based regimen improves the liver-safety profile sufficiently to support a regulatory path forward.
4. Gross-margin recovery and manufacturing obligations
The $62.0M take-or-pay charge and product-related write-offs weighed on third-quarter economics. Investors should watch whether inventory commitments, Roche-related manufacturing activity, and ELEVIDYS volumes allow margins to recover in 2027.
5. 2027 debt and PMO competition
Sarepta has nearly $1B in cash and investments, but its 2027 notes maturity remains a capital-structure issue. At the same time, the potential arrival of a competing exon 51 therapy could test the resilience of its largest current revenue source.
AlgovestIQ Takeaway
Sarepta’s third quarter was operationally better than the headline revenue decline suggests. The PMO franchise delivered $240.3M in product revenue, the company returned to non-GAAP profitability, and management improved both the revenue floor and expense ceiling for 2026.
Still, the commercial recovery is incomplete. ELEVIDYS generated $83.5M in the quarter, and management is guiding to a similar result in the fourth quarter rather than a near-term rebound. The narrower ambulatory-only label has materially reduced the addressable population, while manufacturing take-or-pay charges illustrate the financial consequences of lower-than-expected demand.
The next shift in the investment case depends on evidence rather than messaging. Positive DM1 and FSHD data could give Sarepta credible late-stage pipeline opportunities beyond Duchenne, while supportive ENDEAVOR Cohort 8 data could reopen a regulatory discussion around non-ambulatory ELEVIDYS use. Conversely, weak biological signals, safety limitations, or an inability to convert physician education into sustained ELEVIDYS demand would leave the company more dependent on its mature PMO franchise.
For now, Sarepta has the liquidity and commercial cash generation to pursue those milestones. The central question is whether its pipeline and ELEVIDYS evidence package can restore a clearer growth path before competitive pressure and upcoming debt considerations become more prominent.
How did SRPT stock react?
SRPT closed at $17.82 on Nov 6, 2026, up 1.4% from $17.57 on Nov 5, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 5, 2026 (before release) | $17.57 | — |
| Nov 6, 2026 | $17.82 | +1.4% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- MRNAModerna Q3 2026 Earnings: Raised Revenue Outlook as COVID Sales and Cost Cuts Restore ProfitabilityNov 6, 2026
- BNTXBioNTech Q3 2026 Earnings: BMS Collaboration Revenue Lifts Quarter as Oncology Pipeline Takes Center StageNov 3, 2026
- RXRXRecursion Q3 2026 Earnings: Clinical Progress and Financing Extend Runway Into 2029Nov 3, 2026
- RAREUltragenyx Q3 2026 Earnings: Cost Reset and Gene-Therapy Launches Put 2027 Profitability in FocusNov 3, 2026
- VRTXVertex Q3 2026 Earnings: Revenue Growth Holds as Crinetics Acquisition Reshapes the Cost BaseNov 2, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Sarepta Therapeutics Q3 FY2026 earnings call transcript, as of Nov 5, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Sarepta Therapeutics Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 5, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 5, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.